Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow KALA BIO, Inc.

Get SEC filing alerts via email and in your feed for KALA BIO, Inc.

KALA

KALA BIO, Inc.

About KALA BIO, Inc.

KALA Bio is a biopharmaceutical company focused on developing innovative, cell-free therapies for rare and severe eye diseases. Its lead candidate, KPI-012, targets persistent corneal epithelial defects, leveraging mesenchymal stem cell secretome technology. The company advances clinical trials, seeks regulatory approval, and explores platform applications for other ocular conditions, aiming to improve healing and vision preservation through proprietary biologic solutions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from KALA BIO, Inc.

1
1
KALA BIO, Inc. KALA BIO Reports $1.6 Million Net Loss in Q1 2026, Shifts Focus to AI Platform

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
KALA BIO, Inc. KALA BIO Reports $27M Net Loss for Fiscal Year 2025, Shifts Focus to AI in Biotechnology

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
KALA BIO, Inc. KALA BIO Reports $7.6 Million Net Loss in Q3 2025, Faces Financial Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
KALA BIO, Inc. KALA BIO Reports $11.2 Million Net Loss in Q2 2025, Advances KPI-012 Clinical Trial

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
KALA BIO, Inc. KALA BIO Reports $8.9 Million Net Loss and $2.4 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
KALA BIO, Inc. Kala Bio Reports $38.5 Million Net Loss for 2024, Highlights KPI-012 Development Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
KALA BIO, Inc. KALA Bio Reports Q3 2024 Financial Results, Ongoing Challenges and Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments